摘要
目的利用化学发光免疫法定量检测前列腺特异性抗原(PSA),分析其在临床诊断前列腺癌中的应用情况。方法将60例前列腺癌患者设为A组,60例良性前列腺增生患者设为B组,60例健康体检者设为C组,对三组受试者血清中总前列腺特异性抗原(tPSA),游离前列腺特异性抗原(fPSA)进行化学发光免疫法检测,并分析其水平差异。结果经检测,A组和B组的tPSA含量显著高于C组,而且A组tPSA含量显著高于B组,差异显著,存在统计学意义(P<0.05);另外A组fPSA/tPSA比值低于B组,差异有统计学意义(P<0.05)。结论对PSA进行化学发光免疫法检测,具有较高的临床诊断价值,可为前列腺癌临床诊断提供可靠的参考依据。
Objective To detect the prostate specific antigen （PSA） by chemiluminescence immunoassay, and analyze its significance in patients with prostatic carcinoma. Methods Blood samples from 60 patients with prostatic carcinoma who were treated in our hospital were enrolled into group A; 60 cases of benign prostatic tumor were put into group B and 60 healthy control samples were put into group C. Chemiluminescence immunoassay was used to detect the levels of total prostate specific antigen （tPSA） and free prostate specific antigen （fPSA）, and the results were analyzed by SPSS software. Results The levels of total prostate specific antigen in group A and group B were significantly higher than those of group C, and the levels of group A were lower than those of group B. The ratio of fPSA and tPSA in group A was higher than that of group B. Conclusion Prostate specific antigen detection with chemiluminescence is valuable in diagnosis of prostate cancer. The detection data can provide a reliable reference for the clinical diagnosis of prostatic carcinoma.
出处
《标记免疫分析与临床》
CAS
2016年第7期787-789,共3页
Labeled Immunoassays and Clinical Medicine
关键词
前列腺特异性抗原
化学发光免疫法
前列腺癌
Prostate specific antigen
Chemiluminescence immunoassay
Prostatic carcinoma
